EDS and sleep attacks | Visual hallucinations | Nausea and vomiting | Orthostatic hypotension | ||||||
OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | OR (95%CI) | p value | ||
Sex (male = ref.) | 0.75 (0.43–1.32) | 0.322 | 0.74 (0.40–1.38) | 0.347 | 3.22 (1.77–5.85) | < 0.001 | 0.706 (0.41–1.23) | 0.218 | |
Side of first symptoms (left = ref.) | Both | 0.83 (0.29–2.38) | 0.726 | 0.35 (0.08–1.63) | 0.181 | 1.06 (0.37–3.08) | 0.911 | 1.72 (0.65–4.57) | 0.278 |
Right | 1.14 (0.64–2.03) | 0.660 | 1.30 (0.69–2.46) | 0.412 | 1.07 (0.58–1.97) | 0.824 | 0.98 (0.55–1.74) | 0.933 | |
Tremor-predominant PD (No = ref.) | 0.82 (0.41–1.65) | 0.578 | 0.92 (0.43–1.99) | 0.837 | 0.89 (0.43–1.84) | 0.743 | 0.57 (0.29–1.13) | 0.107 | |
Ever being treated with DAs (No = ref.) | 1.81 (0.91–3.58) | 0.089 | 1.79 (0.84–3.85) | 0.134 | 3.19 (1.41–7.19) | 0.005 | 0.74 (0.40–1.37) | 0.337 | |
Age at diagnosis | 1.00 (0.98–1.02) | 0.871 | 0.97 (0.94–0.99) | 0.006 | 0.97 (0.95–1.00) | 0.026 | 1.01 (0.99–1.04) | 0.281 | |
Disease duration | 1.04 (1.00–1.08) | 0.066 | 1.13 (1.08–1.19) | < 0.001 | 1.02 (0.98–1.06) | 0.366 | 1.04 (1.00–1.08) | 0.080 | |
Levodopa treatment duration | 1.04 (0.99–1.08) | 0.112 | 1.15 (1.09–1.21) | < 0.001 | 1.00 (0.96–1.05) | 0.940 | 1.07 (1.02–1.12) | 0.005 | |
LED at enrolment | 1.00 (1.00–1.00) | 0.106 | 1.00 (1.00–1.00) | 0.004 | 1.00 (1.00–1.00) | 0.869 | 1.00 (1.00–1.00) | 0.085 | |
Peripheral edema | Impulse control disorders | Motor fluctuations | Dyskinesia | ||||||
Sex (male = ref.) | 0.66 (0.33–1.31) | 0.229 | 0.58 (0.26–1.29) | 0.181 | 0.97 (0.57–1.64) | 0.899 | 1.03 (0.61–1.76) | 0.905 | |
Side of first symptoms (left = ref.) | Both | 2.44 (0.79–7.50) | 0.120 | 0.33 (0.04–2.69) | 0.300 | 0.37 (0.13–1.06) | 0.065 | 0.59 (0.21–1.68) | 0.324 |
Right | 1.56 (0.75–3.27) | 0.234 | 1.22 (0.56–2.68) | 0.613 | 1.15 (0.66–2.01) | 0.620 | 1.24 (0.71–2.17) | 0.446 | |
Tremor-predominant PD (No = ref.) | 1.02 (0.43–2.39) | 0.969 | 0.97 (0.37–2.54) | 0.954 | 0.40 (0.19–0.83) | 0.014 | 0.33 (0.16–0.67) | 0.002 | |
Ever being treated with DAs (No = ref.) | 2.44 (0.97–6.14) | 0.058 | 12.00 (1.60–90.21) | 0.016 | 6.82 (3.28–14.19) | < 0.001 | 5.43 (2.50–11.81) | < 0.001 | |
Age at diagnosis | 1.00 (0.97–1.03) | 0.977 | 0.93 (0.90–0.96) | < 0.001 | 0.89 (0.86–0.92) | < 0.001 | 0.88 (0.85–0.91) | < 0.001 | |
Disease duration | 1.010 (0.96–1.06) | 0.682 | 1.04 (0.99–1.0) | 0.114 | 1.44 (1.31–1.58) | < 0.001 | 1.33 (1.24–1.44) | < 0.001 | |
Levodopa treatment duration | 1.03 (0.98–1.08) | 0.310 | 1.01 (0.95–1.07) | 0.872 | 1.42 (1.29–1.56) | < 0.001 | 1.32 (1.22–1.42) | < 0.001 | |
LED at enrolment | 1.00 (1.00–1.00) | 0.212 | 1.00 (1.00–1.00) | 0.140 | 1.01 (1.00–1.01) | < 0.001 | 1.00 (1.00–1.00) | < 0.001 |